Symbols

CHRS

Coherus Oncology·NASDAQ

--(--)

CHRS fundamentals

CHRS Q4 2025 Earnings Preview

Coherus Oncology (CHRS) expects to report earnings on Mar 9, 2026, with estimated revenue of 13.91M (YoY -74.31%), and EPS at -0.3551 (YoY +19.30%).

Revenue estimate / YoY

13.91M

-74.31%

EPS estimate / YoY

-0.3551

+19.30%

Report date

Mar 9, 2026

Earnings Call

4:30 PM on Mar 9, 2026

Meeting link.

Earnings

EPS

Revenue

Revenue & Expenses

CHRS has released its 2025 Q3 earnings report, with revenue of 11.57M, reflecting a YoY change of 91.19%, and net profit of -35.53M, showing a YoY change of -230.49%. The Sankey diagram below clearly presents CHRS's revenue sources and cost distribution.

Key Indicators

Coherus Oncology (CHRS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Coherus Oncology (CHRS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Coherus Oncology (CHRS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Coherus Oncology (CHRS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown